Roivant Sciences, Inc.
NEWS
The $7 billion transaction by Datavant with Ciox Health will be the nation’s largest “neutral and secure health data ecosystem.”
Roivant Sciences is combining with Montes Archimedes Acquisition Corp (MAAC). Once the deal is closed, outstanding shares and warrants of MAAC will be traded for newly issued shares and warrants of the company.
Enzyvant has resubmitted its Biologics Licensing Application to the U.S. FDA for its tissue-based regenerative pediatric congenital athymia therapy RVT-802.
The Silicon Therapeutics acquisition is designed to complement Roivant’s targeted protein degradation platform.
Tapinarof’s potential remittive effects could hold even more value for long-term psoriasis suffers. For patients coming into the trial with a PGA score of 0 (n=78), median time to the disease worsening (defined as a PGA score of ≥2) after discontinuing treatment was approximately 115 days, or 4 months.
If you know Roivant as a brand you might be familiar with Vivek Ramaswamy too. Recently, he stepped down as CEO and became Executive Chairman. Let’s know more.
Roivant Sciences announced its targeted protein degradation platform, with its first pipeline candidate expected to enter the clinic in 2021.
Biopharma and life sciences groups from across the globe provide updates on their business and pipelines.
A summary of daily Biopharma industry news. Please check out stories that are trending on March 19, 2020.
JOBS
IN THE PRESS